Stockholm – September 24, 2026 -- Sobi (STO: SOBI) will present new clinical data on its rare-disease drug Gamifant (emapalumab) at the 2026 Annual Meeting of the Histiocyte Society (HS2026), running September 26-29 in Rotterdam, the Netherlands, with a pooled survival analysis nominated for the meeting's top poster prize.
Pooled transplant-survival analysis earns Robert J. Arceci Prize nomination
The accepted abstract set includes a new pooled analysis of pre- and post-transplant survival outcomes in primary haemophagocytic lymphohistiocytosis (HLH), drawing on data across three prospective trials. Sobi said the analysis was selected as one of the ten highest-scoring poster abstracts at HS2026 and has been nominated for the Robert J. Arceci Prize for Best Poster.
Chinese patient data and encore analyses round out HS2026 abstract slate
Alongside the pooled analysis, Sobi will present two encore analyses of primary HLH outcomes and results from a post-authorisation study conducted in treatment-experienced patients in China. Primary HLH is a rare, life-threatening hyperinflammatory disease.
"Sobi is continuing to build the evidence on treatment and transplant outcomes in primary HLH to help people with this rare, life-threatening hyperinflammatory disease," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi, adding that the poster's ranking "is highly encouraging as it recognises our scientific impact."
Gamifant remains the only approved anti-interferon gamma antibody on the US market
Gamifant works by binding to and neutralising interferon gamma (IFNy), the cytokine responsible for uncontrolled hyperinflammation in HLH, and is administered via a one-hour intravenous infusion. In the US, it is approved for adult and paediatric patients with primary HLH who have refractory, recurrent or progressive disease or intolerance to conventional HLH therapy, as well as for HLH/macrophage activation syndrome (MAS) associated with Still's disease in patients with inadequate response or intolerance to glucocorticoids, or with recurrent MAS.